BACKGROUND Psoriasis is a disease of worldwide distribution with a prevalence of 1 to 3%. Nail psoriasis is estimated in 50% of patients with psoriasis, and in the presence of joint involvement, it can reach 80%. OBJECTIVE To study the nail changes - and their clinical implications - presented by patients with psoriasis vulgaris under surveillance in a university hospital from the south of Br...

Background: Psoriasis is a T cell-mediated autoimmune disease with elevated level of pro-inflammatory cytokines belonging mainly to Th1 pathway. We investigated whether treatment with micronutrients along with methotrexate (MTX) is able to modulate mRNA expression of Th1 and Th2 patterns and its correlation with disease severity. Methods: Thirty plaque type psoriasis patients with Psoriasis ...

To identify diagnostic markers of psoriasis vulgaris and psoriatic arthritis, autoantibodies in sera from patients with psoriasis were screened by two-dimensional immunoblotting (2D-IB). We previously found 22 autoantigens each in psoriasis sera. In this study, serum levels of valosin-containing protein (VCP) in patients, one of the identified autoantigens in psoriasis patients, were studied by...

INTRODUCTION Good treatment adherence is important in the effective management of psoriasis and is related to both the frequency of applications and the amount of product used versus the recommended dose. The efficacy and safety of fixed combination calcipotriol 50 µg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) in the treatment of psoriasis is well established; an aerosol foam formu...

BACKGROUND Psoriasis is an inflammatory disease that not only affects the skin but can also have systemic implications such as obesity and nutritional deficiencies. Carotenoids are vitamin A provitamins with anti-oxidant properties that are present in human tissues including skin. OBJECTIVES To determine whether psoriasis is associated with lower levels of skin carotenoid levels. METHODS In...

Several tools have been introduced in clinical trials to quantify the severity and the response to a given therapeutic regimen of both psoriasis and psoriatic arthritis. Each method present specific advantages and limitations. Here we will discuss some of the most popular clinical outcome measures of both psoriasis (Psoriasis Severity Index, Physician Global Assessment, National Psoriasis Funda...

Pain and discomfort are common and often severe skin symptoms in patients with psoriasis. However, no studies have investigated skin pain and discomfort over time, or factors that explain changes in these symptoms. The aims of the present study were to describe the changes in skin pain, skin discomfort and Psoriasis Area and Severity Index (PASI) over time, and to investigate whether change in ...

BACKGROUND The Psoriasis Area and Severity Index (PASI) is the score of choice to grade psoriasis severity and detect clinical changes. Due to low resolution based on the calculation of the score by fixed area classes, PASI scores <10 have little value. METHODS At 756 patient examinations, psoriasis activity was measured with both PASI and PrecisePASI. RESULTS PrecisePASI has a linear incre...

There are no direct comparison data between infliximab and entanercept in the treatment of psoriasis. This study was a mult icenter, randomised control trial done in the Netherlands to compare the efficacy, outcome of etanercept vs. infliximab in the management of moderate to severe chronic plaque psoriasis. Patients (age 1875 years old) with Psoriasis Area and Severity Index (PASI) ≥10 and/or ...